First AD

Second AD

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

Video content above is prompted by the following:

Please discuss the recent findings from the 

 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Recent Advances in the Treatment of Advanced   HER2+ Breast Cancer: SABCS 2024 

Peer Exchange

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.